The Rosen Law Firm is investigating a class action lawsuit against The Ensign Group following allegations that the company provided misleading business information. This comes after a short seller report accused Ensign of understaffing nursing homes and misusing taxpayer funds, causing an 8.15% stock drop on June 8, 2026. Investors who purchased Ensign securities may be eligible for compensation through a contingency fee arrangement. The Rosen Law Firm, known for its expertise in securities class actions, is preparing to represent affected shareholders in recovering losses.
Elizabeth Crain, a director at Core Scientific, has purchased 6,000 shares of the company. This insider buying may indicate her confidence in the company's future prospects. Such moves often attract investor attention as they can signal positive expe...
Hyperscale Data has stopped Bitcoin mining to focus on AI data center services, backed by a $1.2 billion contract at its Michigan facility. The company's assets, including cash and Bitcoin, are worth nearly double its market cap, suggesting undervalu...
Casey's General Stores reported strong Q1 2026 results, surpassing analyst expectations with an EPS of $7.37 versus $6.78 estimated and revenue of $5.68 billion beating the $5.56 billion forecast. Net income rose 27.1% year-over-year to $273.7 millio...
Academy Sports and Outdoors will announce its Q2 2026 earnings on September 9, with revenue expected to rise 3.8% year-over-year to about $1.66 billion. Analysts forecast earnings per share between $2.07 and $2.12, up from $1.94 last year, indicating...
Pharvaris's experimental oral drug deucrictibant showed an 83% reduction in hereditary angioedema (HAE) attacks in a Phase 3 trial, prompting Oppenheimer to raise its price target from $50 to $75 and maintain an "Outperform" rating. The positive tria...
